ReviewThe Clinical biochemist. Reviews2019
The Paraprotein - an Enduring Biomarker.
Review in The Clinical biochemist. Reviews, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 22 citations in OpenAlex.
- Mass spectrometry vs immunofixation for treatment monitoring in multiple myeloma.Blood advances · 2022Trial
- Liquid Biopsy in Hematologic Malignancies: Advances, Challenges, and Future Directions.Asia-Pacific journal of clinical oncology · 2026Review
- Predictive Role of Soluble B-Cell Maturation Antigen in Short-Term Monitoring of Differently Treated Multiple Myeloma Patients: A Prospective Study.Journal of clinical laboratory analysis · 2025Article
- Expert-level detection of M-proteins in serum protein electrophoresis using machine learning.Clinical chemistry and laboratory medicine · 2024Article
- Clinical Spectrum of Monoclonal Protein and the Factors Associated with Lymphoplasmacytic Malignancies.Journal of clinical medicine · 2024Article
- Review
- Prognostic significance of β2-microglobulin decline index in multiple myeloma.Frontiers in oncology · 2024Article
- Serum-free light chain test utilisation at a South African academic laboratory and comparison with serum protein electrophoresis results.African journal of laboratory medicine · 2023Article
- Multiple Myeloma: Possible Cure from the Sea.Cancers · 2022Review
- The Sec61 translocon is a therapeutic vulnerability in multiple myeloma.EMBO molecular medicine · 2022Article
- A Personalized Mass Spectrometry-Based Assay to Monitor M-Protein in Patients with Multiple Myeloma (EasyM).Clinical cancer research : an official journal of the American Association for Cancer Research · 2021Article
- Immunoglobulin M Paraproteinaemias.Cancers · 2020Review
- Proposed Addendum to 2012 Recommendations for Standardised Reporting of Protein Electrophoresis in Australia and New Zealand.The Clinical biochemist. Reviews · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The 'paraprotein', also known as M-protein, monoclonal protein and monoclonal component, has stood the test of time as the key biomarker in monoclonal gammopathies. It continues to reinvent itself as new electrophoretic and immunoassay methods are developed that are analytically more sensitive. Use of the serum free light chain immunoassay in particular has led to new clinical discoveries and improvements in the diagnosis and monitoring of patients with plasma cell dyscrasia and other monoclonal gammopathies. In addition, minimal residual disease can be detected using mass spectrometry and flow cytometry methods.
Identifiers
30828116PMC6370287W2996741077What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.